<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Photodynamic therapy (<z:chebi fb="7" ids="53228">PDT</z:chebi>) is an FDA-approved minimally invasive medical treatment modality that utilizes light in the presence of oxygen to activate photosensitizing agents that are relatively selectively concentrated in abnormal or neoplastic cells resulting in cell <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>At the present time, <z:chebi fb="7" ids="53228">PDT</z:chebi> has been approved for clinical treatment in the United States, European Union, Canada, Russia, and Japan </plain></SENT>
<SENT sid="2" pm="."><plain>In the United States, US Food and Drug administration approval has been given for the use of <z:chebi fb="7" ids="53228">PDT</z:chebi> in the treatment of <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>, obstructing <z:hpo ids='HP_0011459'>esophageal carcinoma</z:hpo> and early and obstructing tracheobronchial <z:mp ids='MP_0002038'>carcinoma</z:mp> using the photosensitizer Photofrin; <z:mpath ids='MPATH_151'>actinic keratosis</z:mpath> using the photosensitizer Levulan (<z:chebi fb="0" ids="17549">aminolevulinic acid</z:chebi>); and <z:hpo ids='HP_0000608'>macular degeneration</z:hpo> using the photosensitizer BPD </plain></SENT>
<SENT sid="3" pm="."><plain>In the EU the above noted indications have also been approved in addition to the treatment of early <z:e sem="disease" ids="C0278996" disease_type="Neoplastic Process" abbrv="">head and neck cancers</z:e> and palliative treatment of <z:e sem="disease" ids="C0278996" disease_type="Neoplastic Process" abbrv="">head and neck cancer</z:e> using the photosensitizer <z:chebi fb="0" ids="9437">Foscan</z:chebi>; and treatment of basal and squamous cell <z:e sem="disease" ids="C0007114" disease_type="Neoplastic Process" abbrv="">skin cancers</z:e> using the photosensitizer Metvix </plain></SENT>
</text></document>